Fundraising Fox

Thiogenesis Therapeutics

Toronto, US · Founded 2018 · Ontario, Canada corporation

Thiogenesis Therapeutics is a clinical-stage biopharmaceutical company developing sulfur-based therapeutic compounds to treat oxidative stress and inflammation in mitochondrial diseases. The company is advancing TTI-0102, a novel cysteamine prodrug candidate, for rare inherited and acquired mitochondrial disorders including nephropathic cystinosis and Leigh syndrome.

BiotechHealthtechMedical Devices

Founders & leadership

Thiogenesis Therapeutics was founded in 2018 by Patrice Rioux and Dr. Rioux.

PR
Patrice RiouxCo-founder
DR
Dr. RiouxCo-founder, Director and Chief Executive Officer
BG
Brook G. RigginsExecutive
NA
Neil A. JohnsonExecutive

Board

WH
W. Hogan MullallyBoard director
CS
Christopher StarrBoard director
KT
Kim TsuchimotoBoard director
DS
Dr. StarrChairman

Reported raises · per SEC filings

Form D private placements

$877.8K disclosed across 5 rounds · 2021–2026

▶$29KraisedJun 2026 · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrice RiouxExecutive Officer, Director
  • W. Hogan MullallyDirector
  • Kim TsuchimotoDirector
  • Brook G. RigginsExecutive Officer, Director
  • Christopher StarrDirector
Offering amount
$29K
Amount sold
$29K
First sale
Jun 2026
Incorporated
Corporation, Ontario, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$125.5KraisedAug 2025 · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrice RiouxExecutive Officer, Director
  • W. Hogan MullallyDirector
  • Brook G. RigginsExecutive Officer, Director
  • Christopher StarrDirector
  • Kim TsuchimotoDirector
Offering amount
$125.5K
Amount sold
$125.5K
First sale
Jul 2025
Incorporated
Corporation, Ontario, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$252.3KraisedDec 2023 · 1 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Kim TsuchimotoDirector
  • Patrice RiouxExecutive Officer, Director
  • Christopher StarrDirector
  • W. Hogan MullallyDirector
  • Brook G. RigginsExecutive Officer, Director
Offering amount
$252.3K
Amount sold
$252.3K
First sale
Dec 2023
Incorporated
Corporation, Ontario, Canada, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$218.3KraisedNov 2022 · 3 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Hogan W. MullallyDirector
  • Kim TsuchimotoDirector
  • Patrice RiouxExecutive Officer, Director
  • Brook RigginsExecutive Officer, Director
  • Christopher StarrDirector
Offering amount
$218.3K
Amount sold
$218.3K
First sale
Nov 2022
Incorporated
Corporation, Ontario, Canada, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$252.8KraisedAug 2021 · 2 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Neil A. JohnsonExecutive Officer, Director
  • W. Hogan MullallyDirector
  • Brook G. RigginsExecutive Officer, Director
Offering amount
$252.8K
Amount sold
$252.8K
First sale
Jul 2021
Incorporated
Corporation, Ontario, Canada, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conferencebarchart.com · Apr 2026Thiogenesis Raises over C$4.14 Million in Non-Brokered Private Placement of Common Sharesfinance.yahoo.com · Aug 2025Thiogenesis Therapeutics Secures DTC Eligibility, Strengthens U.S. Market Position | TTIPF Stock Newsstocktitan.net · Nov 2024

Frequently asked questions

What does Thiogenesis Therapeutics do?
Thiogenesis Therapeutics is a clinical-stage biopharmaceutical company developing sulfur-based therapeutic compounds to treat oxidative stress and inflammation in mitochondrial diseases. The company is advancing TTI-0102, a novel cysteamine prodrug candidate, for rare inherited and acquired mitochondrial disorders including nephropathic cystinosis and Leigh syndrome.
Who founded Thiogenesis Therapeutics?
Thiogenesis Therapeutics was founded by Patrice Rioux, Dr. Rioux in 2018.
How much funding has Thiogenesis Therapeutics raised?
Thiogenesis Therapeutics has disclosed $877.8K raised across 5 rounds.
Where is Thiogenesis Therapeutics headquartered?
Thiogenesis Therapeutics is headquartered in Toronto, US.
Thiogenesis Therapeutics — Investors & Founders | Fundraising Fox